Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Latest Articles

  • Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum
    Control Bionics Moves to Fully Acquire NeuroBounce Program as EMG-Based Performance Tech Gains Momentum
    • News

  • SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    SKS Technologies Moves to Expand NSW Footprint With Delta Elcom Acquisition
    • News

  • Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    Monash University Partners with HITIQ to Advance Concussion Science Using Smart Mouthguards
    • News

  • Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    Harris Technology targets return to profitability amid surging Refurbished Tech sales and Apple expansion
    • News

  • Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    Pivotal Metals Secures $5.4M to Fast-Track Quebec Drill Program
    • News

  • Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise
    • News

  • DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment
    • News

  • Stakk Secures T-Mobile Contract to Power Super App Expansion
    Stakk Secures T-Mobile Contract to Power Super App Expansion
    • News

  • Medibank Backs Emyria with Landmark Depression Care Deal
    Medibank Backs Emyria with Landmark Depression Care Deal
    • News

  • NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI
    • News

Health Insurer adds cannabis to coverage with Little Green Pharma partnership

  • In News
  • November 10, 2020
  • Alfred Chan
Health Insurer adds cannabis to coverage with Little Green Pharma partnership

Members of private health insurer Health Insurance Fund (HIF) will be given priority access to Little Green Pharma (ASX: LGP) and their research into medicinal cannabis with the two commencing a strategic partnership focused on improving patient quality of life. 

Under the partnership, HIF members will be given priority participation in Little Green Pharma product trials, as well as rebates on medicinal cannabis products as part of their membership. 

“Our company has always had Australian patient access at the forefront. We were the first company in Australia to launch with locally-grown and affordable medicinal cannabis products,” said Little Green Pharma Managing Director, Fleta Solomon. 

“Our disruptive pricing strategy led to the cost of medicinal cannabis products being significantly reduced in price nationally.” 

“We are proud to further contribute to driving improved affordability and our partnership with HIF, another patient-focused company, will mean better access to medicinal cannabis products for patients across Australia.”

While the partnership does not bring with it any material value to Little Green Pharma initially, it highlights changing attitudes in Australia toward medicinal cannabis which will undergo considerable change in 2021. 

It is expected that in February 2021, the final regulatory approval will be passed to de-schedule cannabidiol (CBD) from a Schedule 4 drug to Schedule 3, enabling Australians to purchase CBD products over-the-counter upon consultation from a pharmacist, without the need for a prescription.

For the quarter ending 30 September 2020, Little Green Pharma reported record sales revenue of $1.29 million from more than 8,500 products sold, a 41% increase on the previous quarter

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  •  
  •  
  •  
  •  
  • asx lgp
  • cannabidiol
  • Fleta Solomon
  • health insurance fund
  • lgp
  • Little green pharma
  • medicinal cannabis
  • News

Leave a Comment

You must be logged in to post a comment.

  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024

Login or register for free to access unlimited reading

Register Now!
  • About
  • Latest Posts
Alfred Chan
Alfred Chan is a Business Reporter at The Sentiment specialising in ASX-listed small cap companies, a bloodstock enthusiast and former equities analyst.
Latest posts by Alfred Chan (see all)
  • Harris Technology to expand refurbished tech division amid rising demand from cost-conscious Australians - April 30, 2025
  • Harris Technology secures major investment from Taiwan’s FSP Technology at 100% premium - March 10, 2025
  • ARC Funds acquires 30% of auzbiz Capital as latest direct-to-investor marketing venture - October 8, 2024
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.